Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies... Show more
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NVG | 11.75 | N/A | N/A |
| Nuveen AMT-Free Municipal Credit Income Fund | |||
| FLBR | 17.53 | N/A | N/A |
| Franklin FTSE Brazil ETF | |||
| RSPC | 36.18 | N/A | N/A |
| Invesco S&P 500® Eql Wght Comm Svcs ETF | |||
| AGRH | 25.75 | -0.04 | -0.14% |
| iShares Interest Rt Hdg U.S. Aggt Bd ETF | |||
| GII | 66.00 | -0.35 | -0.53% |
| SPDR® S&P® Global Infrastructure ETF | |||
A.I.dvisor indicates that over the last year, CLYYF has been loosely correlated with ELVAF. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if CLYYF jumps, then ELVAF could also see price increases.
| Ticker / NAME | Correlation To CLYYF | 1D Price Change % | ||
|---|---|---|---|---|
| CLYYF | 100% | N/A | ||
| ELVAF - CLYYF | 47% Loosely correlated | N/A | ||
| REPL - CLYYF | 35% Loosely correlated | +3.55% | ||
| HLVX - CLYYF | 29% Poorly correlated | N/A | ||
| IBIO - CLYYF | 23% Poorly correlated | N/A | ||
| ATHE - CLYYF | 22% Poorly correlated | N/A | ||
More | ||||